Mauna Kea Technologies Posts 44% H1 Sales Growth on Cellvizio Expansion — Mauna Kea Technologies S.A.

Event summary

H1 2026 sales reached €3.2M, up 44% at constant exchange rates (+39% as reported), driven by Cellvizio adoption in pancreatic cysts and CellTolerance expansion.
CellTolerance revenue surged +142% YoY, with EMEA & ROW sales up +261%, supported by direct patient-pay model penetration in new markets (UAE, Switzerland, Spain).
U.S. probe sales grew +33% CER, with pricing power strengthening as average discounting fell from 23% to 10% on AQ-Flex.
Company secured €4M shareholder loan facility in July 2026, extending financial visibility beyond 2027.

The big picture

Mauna Kea's strong H1 performance reflects strategic bets on high-value indications (pancreatic cysts) and a scalable commercial model for CellTolerance. The €4M loan facility underscores investor confidence in the company's trajectory, but execution risks remain tied to U.S. system sales volatility and international expansion pacing. The broader shift toward real-time cellular imaging in gastroenterology positions Mauna Kea as a key player in a $25B+ therapeutic market.

What we're watching

U.S. Market Momentum: Whether Mauna Kea can sustain H2 system sales growth amid seasonal hospital capital purchase cycles and platform upgrade conversions.
CellTolerance Scaling: The pace at which CellTolerance ramps up in newly opened territories, particularly under the direct patient-pay model.
Profitability Timeline: How operational leverage and cost discipline will impact the path to profitability by year-end 2027.